Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
5.91
+0.17 (2.96%)
May 29, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 117.05 | 116.59 | 105.76 | 113.45 | 102.29 | 7.34 | |
Revenue Growth (YoY) | 16.30% | 10.24% | -6.78% | 10.91% | 1293.98% | -82.48% |
Cost of Revenue | 5.75 | 5.42 | 3.88 | 4.64 | 4.79 | 7.38 |
Gross Profit | 111.3 | 111.17 | 101.87 | 108.81 | 97.5 | -0.04 |
Selling, General & Admin | 91.54 | 85.98 | 73.62 | 75.82 | 71.61 | 18.96 |
Research & Development | 17.34 | 13.7 | 12.02 | 13.78 | 16.69 | 68.89 |
Other Operating Expenses | 2.56 | 0 | 0.07 | 86.44 | - | - |
Total Operating Expenses | 111.44 | 99.69 | 85.71 | 176.04 | 88.29 | 87.85 |
Operating Income | -0.14 | 11.49 | 16.16 | -67.23 | 9.2 | -87.89 |
Interest Income | 0.51 | 1.75 | 1.55 | 1.04 | 1.58 | - |
Other Non-Operating Income (Expense) | -1.04 | 1.2 | 5.51 | -10.78 | -1.37 | -0.04 |
Total Non-Operating Income (Expense) | -0.53 | 2.95 | 7.06 | -9.74 | 0.21 | -0.04 |
Pretax Income | 0.56 | 14.44 | 23.22 | -76.97 | 9.41 | -87.93 |
Provision for Income Taxes | 4.28 | 4.56 | 5.32 | 8.52 | 5.1 | - |
Net Income | -6.36 | 5.03 | 12.09 | -92.93 | 2.3 | -87.93 |
Minority Interest in Earnings | 2.65 | 4.85 | 5.81 | 7.45 | 2.01 | - |
Net Income to Common | -6.36 | 5.03 | 12.09 | -92.93 | 2.3 | -87.93 |
Net Income Growth | - | -58.40% | - | - | - | - |
Shares Outstanding (Basic) | 91 | 89 | 85 | 66 | 64 | 61 |
Shares Outstanding (Diluted) | 97 | 103 | 102 | 66 | 76 | 67 |
Shares Change (YoY) | -0.92% | 0.87% | 55.39% | -13.02% | 13.45% | 5117.44% |
EPS (Basic) | -0.08 | 0.06 | 0.14 | -1.41 | 0.04 | 0.26 |
EPS (Diluted) | -0.09 | 0.02 | 0.05 | -1.41 | 0.03 | 0.24 |
EPS Growth | - | -60.00% | - | - | -87.50% | - |
Shares Outstanding | 91.34 | 91.31 | 86.31 | 76.6 | 63.59 | 2.09 |
Free Cash Flow | 3.07 | -0.18 | -5.96 | 17.38 | 5.69 | -84.59 |
Free Cash Flow Growth | - | - | - | 205.25% | - | - |
Free Cash Flow Per Share | 0.03 | -0.00 | -0.06 | 0.26 | 0.08 | -1.27 |
Gross Margin | 95.09% | 95.35% | 96.33% | 95.91% | 95.31% | -0.57% |
Operating Margin | -0.12% | 9.85% | 15.28% | -59.26% | 9.00% | -1197.79% |
Profit Margin | -3.17% | 8.47% | 16.92% | -75.35% | 4.22% | -1198.32% |
FCF Margin | 2.63% | -0.15% | -5.63% | 15.32% | 5.56% | -1152.82% |
EBITDA | 2.48 | 13.97 | 17.71 | -66.16 | 10.29 | -87.6 |
EBITDA Margin | 2.12% | 11.98% | 16.75% | -58.31% | 10.06% | -1193.84% |
EBIT | -0.14 | 11.49 | 16.16 | -67.23 | 9.2 | -87.89 |
EBIT Margin | -0.12% | 9.85% | 15.28% | -59.26% | 9.00% | -1197.79% |
Effective Tax Rate | 758.16% | 31.56% | 22.91% | -11.06% | 54.16% | 0.00% |